Working capital intensity remains high
IPO proceeds of ₹20 crore are earmarked for working capital, indicating structurally high inventory and receivable requirements.
AAKAARMEDICALTECHNOLOGIE / bear-case history
Track the concerns that keep returning.
Aakaar Medical Technologies · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
medium
H2 margin sustainability questioned
Analyst asked if 26% EBITDA margin in H2 was sustainable or due to one-off lower conference costs; management acknowledged H2 typically has lower expenses.
Deferred demand normalization risk
H2 revenue growth of 64% HoH may partly reflect deferred demand from H1 credit tightening; FY27 growth could normalize.
Dependence on new product launches
Growth hinges on successful ramp-up of new products (Latigo, VM exosomes) which faced regulatory delays; any further delays could impact revenue.